- Conditions
- Asthma
- Interventions
- Fluticasone / Salmeterol, Placebo, Advair Diskus 100/50
- Drug
- Lead sponsor
- Roxane Laboratories
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 100
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Surprise, Arizona + 75 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Asthma
- Interventions
- VR506
- Drug
- Lead sponsor
- Vectura Limited
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Denver, Colorado • Celebration, Florida + 8 more
- Conditions
- Asthma
- Interventions
- VR506, Placebo
- Drug
- Lead sponsor
- Vectura Limited
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 374 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 32
- States / cities
- Fountain Valley, California • Los Angeles, California • Mission Viejo, California + 28 more
- Conditions
- Asthma
- Interventions
- VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with mouthpiece, VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with facemask, 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece, 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask, 0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece, 0.5 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with facemask
- Combination Product
- Lead sponsor
- Vectura Limited
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 2
- States / cities
- Tempe, Arizona • Anaheim, California
- Conditions
- Wheezing, Reactive Airway Disease, Mild Asthma
- Interventions
- VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System, 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer
- Combination Product
- Lead sponsor
- Vectura Limited
- Industry
- Eligibility
- 4 Years to 8 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Colorado Springs, Colorado • Raleigh, North Carolina • Tulsa, Oklahoma
- Conditions
- Cough, Wheezing
- Interventions
- VR647 Inhalation System + VR647 Smart Card 3 Secs, VR647 Inhalation System + VR647 Smart Card 2 Secs, VR647 Inhalation System + VR647 Smart Card 4 Secs
- Combination Product
- Lead sponsor
- Vectura Limited
- Industry
- Eligibility
- 1 Year to 5 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 5
- States / cities
- Mission Viejo, California • Plymouth, Minnesota • St Louis, Missouri + 2 more